Stockscreener 앱 받기
516.74
0.45%
-2.35
전일 마감가:
$519.09
열려 있는:
$520.09
하루 거래량:
179.83K
Relative Volume:
0.51
시가총액:
$11.94B
수익:
$1.13B
순이익/손실:
$-309.44M
주가수익비율:
-40.37
EPS:
-12.8001
순현금흐름:
$-275.41M
1주 성능:
+1.81%
1개월 성능:
-5.50%
6개월 성능:
+18.79%
1년 성능:
+26.94%
1일 변동 폭
$514.90
$530.67
1주일 범위
$506.85
$542.77
52주 변동 폭
$393.61
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
명칭
Madrigal Pharmaceuticals Inc
전화
404-380-9263
주소
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
516.74 | 11.99B | 1.13B | -309.44M | -275.41M | -12.80 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-06 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-02-28 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | 재확인 | H.C. Wainwright | Buy |
| 2024-06-28 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-04-22 | 개시 | BofA Securities | Underperform |
| 2024-03-15 | 업그레이드 | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-02-26 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 재확인 | Oppenheimer | Outperform |
| 2022-12-19 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-19 | 재확인 | Piper Sandler | Overweight |
| 2022-12-19 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-11-24 | 재개 | Evercore ISI | Outperform |
| 2020-11-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-05 | 개시 | BMO Capital Markets | Market Perform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-01-30 | 개시 | Canaccord Genuity | Buy |
| 2020-01-09 | 업그레이드 | UBS | Neutral → Buy |
| 2019-11-07 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-06-10 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-12-12 | 개시 | B. Riley FBR | Neutral |
| 2018-11-19 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 개시 | Citigroup | Buy |
| 2018-08-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2018-06-28 | 개시 | Raymond James | Mkt Perform |
모두보기
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug - Stocktwits
Madrigal Pharmaceuticals' General Counsel Executes Automatic Sale of 664 Shares to Cover Tax Withholding - Kalkine Media
Shannon Kelley Sells 664 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule - TradingView
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal (NASDAQ: MDGL) GC has 664 shares sold for RSU taxes - Stock Titan
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow - simplywall.st
Exploring 3 High Growth Tech Stocks In The US Market - Sahm
Madrigal Adds J&J R&D Chief to Board as MASH Push Expands - MyChesCo
Madrigal (NASDAQ: MDGL) awards Reed 647 RSUs and options on 1,078 shares - Stock Titan
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A Biotech Powerhouse with 33.59% Upside Potential - DirectorsTalk Interviews
Madrigal (NASDAQ: MDGL) officer plans $337K sell-to-cover trade - Stock Titan
2,410 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by State of Wyoming - MarketBeat
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands - MarketBeat
Madrigal Uses Equity Awards to Recruit 10 Employees - MyChesCo
Madrigal Pharmaceuticals Inc (0JXI) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Madrigal Pharmaceuticals Adds Renowned Leader to Board - The Globe and Mail
Dimensional Fund Advisors LP Has $4.46 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Appoints Dr. John C. Reed to Expanded Board with Detailed Compensation Plan - Kalkine Media
Madrigal Pharmaceuticals appoints J&J executive to board By Investing.com - Investing.com Australia
Madrigal Pharmaceuticals appoints J&J executive to board - Investing.com
Form 8K Madrigal Pharmaceuticals Inc For: 12 August By Investing.com - Investing.com Canada
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors - The Manila Times
Madrigal Pharmaceuticals, Inc. Announces Appointment of John C. Reed as Board Director - marketscreener.com
Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Royal Bank of Canada - MarketBeat
Madrigal's Board Adds Scientist With More Than 900 Papers - Stock Titan
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Precision Trading with Madrigal Pharmaceuticals Inc. (MDGL) Risk Zones - Stock Traders Daily
Madrigal at Canaccord Genuity growth conference: Rezdiffra gains pace By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH Expansion - webull.com
Madrigal Sets Investor Presentation as MASH Strategy Advances - MyChesCo
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A Promising 32.94% Upside in the Biotech Sector - DirectorsTalk Interviews
Madrigal Pharmaceuticals (MDGL) Holds Ground Near $514 as MASH Franchise Gains TractionKey Reversal Day - Vinanet
Assenagon Asset Management S.A. Buys 108,181 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Bank of America Corp DE Sells 226,498 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - The Manila Times
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Madrigal Pharmaceuticals: Semaglutide Launch No Issue, Wise Pipeline Approach (NASDAQ:MDGL) - Seeking Alpha
California State Teachers Retirement System Buys 3,039 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to Outperform at Wolfe Research - MarketBeat
Madrigal Pharmaceuticals (MDGL) Stock Analysis: A 46% Potential Upside Amid Robust Analyst Support - DirectorsTalk Interviews
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree - Fierce Biotech
Principal Financial Group Inc. Sells 6,022 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal: I Can't Bet Against A Company Performing This Well (Upgrade) - Seeking Alpha
Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is Stronger Rezdiffra Momentum and New Patents Altering The Investment Case For Madrigal Pharmaceuticals (MDGL)? - simplywall.st
Madrigal Pharmaceuticals Shares Slide as Investors Reassess a High Earnings Bar - Quiver Quantitative
Canaccord Genuity Remains a Buy on Madrigal Pharmaceuticals (MDGL) - theglobeandmail.com
Madrigal: Q2 Earnings Snapshot - KING5.com
Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
BlackRock (MDGL holder) discloses 4.6% Madrigal Pharmaceuticals stake in Schedule 13G/A - Stock Titan
Madrigal Pharmaceuticals Inc (MDGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
1.07%
자본화:
|
볼륨(24시간):